AVITA Therapeutics Forecast, price target & analysts
AVITA Therapeutics Target price 2025 - Analyst rating & recommendation
AVITA Therapeutics Classifications & Recommendation:
AVITA Therapeutics Price Target
| Target Price | $16.31 |
| Price | $7.76 |
| Potential |
110.14%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target AVITA Therapeutics 2026 .
The average AVITA Therapeutics target price is $16.31.
This is
110.14%
register free of charge
$25.39
227.17%
register free of charge
$10.18
31.20%
register free of charge
|
|
| A rating was issued by 9 analysts: 6 Analysts recommend AVITA Therapeutics to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AVITA Therapeutics stock has an average upside potential 2026 of
110.14%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 64.25 | 102.43 |
| 28.14% | 59.43% | |
| EBITDA Margin | -86.24% | -16.17% |
| 64.36% | 81.25% | |
| Net Margin | -98.02% | -19.33% |
| 33.22% | 80.28% |
9 Analysts have issued a sales forecast AVITA Therapeutics 2025 . The average AVITA Therapeutics sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an AVITA Therapeutics EBITDA forecast 2025. The average AVITA Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 AVITA Therapeutics Analysts have issued a net profit forecast 2025. The average AVITA Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.39 | -0.75 |
| 70.71% | 68.62% | |
| P/E | negative | |
| EV/Sales | 1.98 |
6 Analysts have issued a AVITA Therapeutics forecast for earnings per share. The average AVITA Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
AVITA Therapeutics...
Current AVITA Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Apr 04 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Apr 04 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 08 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Jan 08 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
